One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry

Billette de Villemeur, Etienne and Versaevel, Bruno (2017): One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry.

Abstract

We draw from documented characteristics of the biopharmaceutical industry to construct a model where two firms can choose to outsource R&D to an external unit, and/or engage in internal R&D, before competing in a final market. We investigate the tension between outsourced and internal operations, the distribution of profits among market participants, and the incentives to coordinate outsourcing activities, or to integrate R&D and production. Consistent with the empirical evidence, we find that: (1) each firm’s internal R&D activity is monotonic in the technology received from the external unit, and the sign of the relationship does not depend on the technology received or generated by the competitor; (2) a measure of direct and indirect technological externalities drives the distribution of industry profits, with lower returns to an external unit involved in research (drug discovery) than in development (clinical trials); (3) upstream entry is stimulated by the long-term perspective for the external unit’s owners to earn a larger share of industry profits by selling out assets to a client firm than by running operations. However, in the case of early-stage research, the delinkage of investment incentives from industry value, and the vulnerability of investors’ returns to negative shocks, both suggest the abandonment of projects with economic and medical value as a likely consequence of R&D outsourcing.

• Item Type: MPRA Paper
• Language: English
• Keywords: research; development; biotechnology; pharmaceuticals; externalities
• Subjects: C - Mathematical and Quantitative Methods > C7 - Game Theory and Bargaining Theory > C72 - Noncooperative Games; L - Industrial Organization > L1 - Market Structure, Firm Strategy, and Market Performance > L13 - Oligopoly and Other Imperfect Markets; O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O31 - Innovation and Invention: Processes and Incentives

References

Aghion, P. and Tirole, J., 1994, “On the management of innovation,” Quarterly Journal of Economics, 109(4), 1185-1209.

Aldrich, S., 2012, “Where are the opportunities in the $36.6 billion market for outsourcing clinical trials?,” Contract Pharma, September issue. Available at: http://www.contractpharma.com/

Allain, M-L., Henry, E. and Kyle, M.K., 2015, “Competition and the efficiency of markets for technology,” Management Science, 62(4), pp. 1000-1019.

Amir, R., Evstigneev, I. and Wooders, J., 2003, “Noncooperative versus cooperative R&D with endogenous spillover rates,” Games and Economic Behavior, 42(2), 183-207.

Anton, J.J. and Yao, D.A., 1994, “Expropriation and inventions: Appropriable rents in the absence of property rights,” American Economic Review, 84(1), 190-209.

Argyres, N.S. and Liebeskind, J.P., 2002, “Governance inseparability and the evolution of US biotechnology industry,” Journal of Economic Behavior and Organization, 47(2), 197-219.

Arora A., Fosfuri, A. and Gambardella, A., 2001, “Markets for technology and their implications for corporate strategy,” Industrial and Corporate Change, 10(2), 419-451.

Arora, A. and Gambardella, A., 1990, “Complementarity and external linkages: The strategies of the large firms in biotechnology,” Journal of Industrial Economics, 38(4), 361-379.

Arora, A. and Gambardella, A., 1994, “The changing technology of technological change: General and abstract knowledge and the division of innovative labour,” Research Policy, 23(5), 523-532.

Arora, A., Gambardella, A., Pammolli, F. and Riccaboni, M., 2004, “The nature and the extent of the market for technology in biopharmaceuticals,” in: Cesaroni, F., Gambardella, A. and Garcia-Fontes, W., editors, R&D, Innovation and Competitiveness in the European Chemical Industry, Ch. 7, Springer, 175-202.

Arora, A., Vogt, W.B. and Yoon, J., 2004, “Does in-house R&D increase bargaining power? Evidence from the pharmaceutical industry”. Available at SSRN: http://ssrn.com/abstract=670304 or http://dx.doi.org/10.2139/ssrn.670304

Azoulay, P. 2004. Capturing knowledge within and across firm boundaries: Evidence from clinical development,” American Economic Review, 94(5), 1591-1612.

Bhattacharya, S. and Guriev, S., 2006, “Patents vs. trade secrets: Knowledge licensing and spillover,” Journal of the European Economic Association, 4(6), 1112-1147.

Bhattacharya, S. and Guriev, S., 2013, “Control rights over intellectual property,” Journal of Industrial Economics, 61(3), 564-591.

Bernheim, B.D. and Whinston, M.D., 1986a, “Common agency,” Econometrica, 54(4), 923-942.

Bernheim, B.D. and Whinston, M.D., 1986b, “Menu auctions, resource allocation, and economic influence,” Quarterly Journal of Economics, 101(1), 1-32.

Bernheim, B.D., Peleg, B. and Whinston, M.D., 1987, “Coalition-proof Nash equilibria: I Concepts,” Journal of Economic Theory, 42(1), 1-12.

Billette de Villemeur, E. and Versaevel, B., 2003, “From private to public common agency,” Journal of Economic Theory, 111(2), pp. 305-309.

Bloom, N., Schankerman, M. and Van Reenen, J., 2013, “Identifying Technology Spillovers and Product Market Rivalry,” Econometrica, 81(4), 1347-1393.

Bower, D.J. and Whittaker, E., 1993, “Global R&D networks,” Industry and Innovation, 1(1), 50-64.

Cassiman, B. and Veugelers, R., 2006, “In search of complementarity in innovation strategy: Internal R&D and external knowledge acquisition,” Management Science, 52(1), 68-82.

Ceccagnoli, M., Higgins, M. and Palermo, V., 2014, “Behind the scenes: sources of complementarity in R&D,” Journal of Economics and Management Strategy, 23(1), 125-148.

Cockburn, I.M. and Henderson, R.M., 2001, “Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research,” Journal of Health Economics, 20(6), 1033-57.

Cremer, J. and Riordan, M.H., 1987, “On governing multilateral transactions with bilateral contracts,” RAND Journal of Economics, 18(3), 436-451.

d’Aspremont, C. and Jacquemin, A., 1988, “Cooperative and noncooperative R&D in duopoly with spillovers,” American Economic Review, 78(5), 1133-1137.

Danzon, P., Nicholson, S. and Sousa Pereira, N., 2005, “Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances,” Journal of Health Economics, 24(2), 317-339.

Danzon, P., Epstein, A. and Nicholson. S., 2007, “Mergers and acquisitions in the pharmaceutical and biotech industries,” Managerial and Decision Economics, 28(4-5), 307-328.

Danzon, A. and Grabowski, H., 2012, “Mergers, acquisitions, and alliances,” in: Danzon, P. and Nicholson, S., editors, The Economics of the Biopharmaceutical Industry, Ch. 18, Oxford University Press, 552-577.

DiMasi, J.A., Hansen, R.W., Grabowski, H.G., and Lasagna, L., 1991, “Cost of innovation in the pharmaceutical industry,” Journal of Health Economics, 10(2),107-142.

DiMasi, J.A., Hansen, R.W., and Grabowski, H.G., 2003, “The price of innovation: new estimates of drug development costs,” Journal of Health Economics, 22(2), 151-185.

DiMasi, J.A., Hansen, R.W., and Grabowski, H.G., 2016, “Innovation in the pharmaceutical industry: New estimates of R&D costs,” Journal of Health Economics, 47(C), 20-33.

Folta, T.B., 1998, “Governance and uncertainty: The trade-off between administrative control and commitment,” Strategic Management Journal, 19(11), 1007-28.

Galambos, L. and Sturchio, J.L., 1998, “Pharmaceutical firms and the transition to biotechnology: A study in strategic innovation,” Business History Review, 72(2), 250-278.

Golec, J. and Vernon, J.A., 2009, “Financial risk of the biotech industry versus the pharmaceutical industry,” Applied Economics and Health Policy, 7(3), 155-65.

Guedj, I., 2005, “Ownership vs. contract: how vertical integration affects investment decisions in pharmaceutical R&D,” McCombs Research Paper Series, No. FIN-01-06.

Hagedoorn, J. and Wang, N., 2012, “Is there complementarity or substitutability between internal and external R&D strategies?,” Research Policy, 41(6), 1072-1083.

Hagedoorn, J. and Hesen, G., 2007, “Contract law and the governance of inter-firm technology partnerships: An analysis of different modes of partnering and their contractual implications,” Journal of Management Studies, 44(3), 342-366.

Henderson, R.M., 1994, “The evolution of integrative competence: Innovation in cardiovascular drug discovery,” Industrial and Corporate Change, 3(3), 607-630.

Henderson, R.M. and Cockburn, I.M., 1996, “Scale, scope and spillovers: the determinants of research productivity in drug discovery,” RAND Journal of Economics 27(1), 32-59.

Henriques, I., 1990, “Cooperative and noncooperative R&D in duopoly with spillovers: Comment,” American Economic Review, 80(3), 638-640.

Higgins, M.J., 2007, “The allocation of control rights in pharmaceutical alliances,” Journal of Corporate Finance, 13(1), 58-75.

Higgins, M.J. and Rodriguez, D., 2006, “The outsourcing of R&D through acquisitions in the pharmaceutical industry,” Journal of Financial Economics, 80(2), 351-383.

Ho, S.J., 2009, “Information leakage in innovation outsourcing,” R&D Management, 39(5), 431-443

Holmström, B., 1989, “Agency costs and innovation,” Journal of Economic Behavior and Organization, 12(3), 305-327.

Keith, J.A., Bigger, L.A., Phyllis A.A., Maes, A.E. and Daems, R., 2013, “Delivering the promise of the Decade of Vaccines: Opportunities and challenges in the development of high quality new vaccines,” Vaccines, 31(S), B184-B193.

Lai, E., Riezman, R. andWang, P., 2009, “Outsourcing of innovation,” Economic Theory, 38(3), 485-515.

Laussel, D. and Le Breton, M., 2001, “Conflict and cooperation: The structure of equilibrium payoffs in common agency,” Journal of Economic Theory, 100(1), 93-128.

Lerner, J. and Malmendier, U., 2010, “Contractibility and the design of research agreements,” American Economic Review, 100(1), 214-246.

Lerner, J. and Merges, R.P., 1998, “The control of technology alliances: An empirical analysis of the biotechnology industry,” Journal of Industrial Economics, 46(2), 125-156.

Leten, B., Kelchtermans, S. and Belderbos, R., 2010, “Internal basic research, external basic research and the technological performance of pharmaceutical firms,” Katholieke Universiteit Department of Managerial Economics, Strategy and InnovationsWorking Paper No. 1003.

Lokshin B., Belderbos R. and Carree M., 2008, “The productivity effects of internal and external R&D: Evidence from a dynamic panel data model,” Oxford Bulletin of Economics and Statistics, 70(3), 399-413.

Macher, J.T. and Boerner, Ch. S., 2006, “Experience and scale and scope Economies: Trade-offs and performance in development,” Strategic Management Journal, 27(9), 845-865.

Majewski, S., 2004, “How do consortia organize collaborative R&D?: Evidence from the national cooperative research act,” Discussion Paper 483, Harvard Law School.

Martimort, D., 1996, “Exclusive dealing, common agency, and multi-principals incentive theory,” RAND Journal of Economics, 27(1), 1-31.

Martimort, D., 2007, “Multi-Contracting Mechanism Design,” in: Blundell, R., NeweyW. and Person, T., editors, Advances in Economic Theory Proceedings of the World Congress of the Econometric Society, Cambridge University Press.

Martimort, D. and Stole, L., 2003, “Contractual externalities and common agency equilibria,” Advances in Theoretical Economics, 3(1).

Mestre-Ferrandiz, J.M., Sussex, J. and Towse, A., 2012, The R&D Cost of a New Medicine. London: Office of Health Economics.

Morton, F.S. and Kyle, M., 2012, “Markets for pharmaceutical products,” in: Pauly M.V., McGuire, T.G. and Barros, P.P., editors, Handbook of Health Economics, Volume 2, Elsevier.

Motta, M., 1992, “Cooperative R&D and vertical product differentiation, International Journal of Industrial Organization, 10(4), 643-661.

Mowery, D.C., 1983, “The relationship between intrafirm and contractual forms of industrial research in American manufacturing, 1900-1940,” Explorations in Economic History, 20(4), 351-374.

Munos, B. 2009, “Lessons from 60 years of pharmaceutical innovation,”Nature Reviews Drug Discovery, 8, 959-968.

Pammolli, F., Magazzini, L. and Riccaboni, M., 2011, “The productivity crisis in pharmaceutical R&D,”Nature Revue Drug Discovery, 10(6), 428-438.

Pennings, E. and Sereno, L., 2011, “Evaluating pharmaceutical R&D under technical and economic uncertainty,” European Journal of Operational Research, 212(2), 374-385.

Pisano, G.P., 1989, “Using equity to support exchange: evidence from the biotechnology industry,” Journal of Law, Economics, and Organization, 5(1), 109-126.

Pisano, G.P., 1991, “The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry,” Research Policy, 20(3), 237-249.

Pisano, G.P., 2006, Science Business: The Promise, the Reality and the Future of Biotech, Harvard Business School Press.

Pisano, G.P., 2010, “The evolution of science-based business: Innovating how we innovate,” Industrial and Corporate Change, 19(2), 465-482.

Pisano, G.P., 2015, “Big pharma needs to get busy in the lab: Blanket generalizations about biotech firms being more efficient are unfounded,” TheWall Street Journal, March 19 (available at: www.wsj.com/articles/big-pharma-needs-to-get-busy-in-the-lab-1426805547).

Robinson, D.T. and Stuart, T.E., 2007, “Financial contracting in biotech strategic alliances,” Journal of Law and Economics, 50(3), 559-595.

Rothaermel, F.T., 2001, “Incumbent’s advantage through exploiting complementary assets via interfirm cooperation,” Strategic Management Journal, 22(6-7), 687-699.

Rydzewski, R.M., 2008, Real World Drug Discovery: A Chemist’s Guide to Biotech and Pharmaceutical Research, Amsterdam: Elsevier.

Scannell, J.W., Blanckley, A., Boldon, H. and Warrington, B., 2012, “Diagnosing the decline in pharmaceutical R&D efficiency”, Nature Reviews Drug Discovery, 11, 191-200.

Scherer, F.M., 2001, “The link between gross profitability and pharmaceutical R&D spending,” Health Affairs, 20(5), pp. 216-220.

Scherer, F.M., 2010, “Pharmaceutical innovation,” in: Hall, B.H. and Rosenberg, N., editors, Handbook of The Economics of Innovation, Vol. 1, Ch. 12, pp. 539-574.

Scherer, F.M., 2011, “R&D costs and productivity in biopharmaceuticals,” Faculty Research Working Paper Series, Harvard Kennedy School, RWP11-046.

Schuhmacher, A., Gassmann, O. and Hinder, M., 2016, “Changing R&D models in research-based pharmaceutical companies,” Journal of Translational Medecine, 14(1), pp. 105.

Spulber, D.F., 2013, “How do competitive pressures affect incentives to innovate when there is a market for inventions?,” Journal of Political Economy, 121(6), 1007-1054.

Symeonidis, G., 2003, “Comparing Bertrand and Cournot equilibria in a differentiated duopoly with product R&D,” International Journal of Industrial Organization, 21(1), 39-55.

Topkis, D., 1995, “Comparative statics of the firm,” Journal of Economic Theory, 67(2), 370-401.

Vencatachellum, D. and Versaevel, B., 2009, “R&D delegation in a duopoly with spillovers,” The B.E. Journal of Economic Analysis & Policy, 9(1) (Contributions), Article 55.

Veugelers, R., 1997, “Internal R&D expenditures and external technology sourcing,” Research Policy, 26(3), 303-316.

Veugelers, R. and Cassiman, B., 1999, “Make and buy in innovation strategies: Evidence from Belgian manufacturing firms,” Research Policy, 28(1), 63-80.

Veugelers, R. and Cassiman, B., 2005, “R&D cooperation between firms and universities: Some empirical evidence from Belgian manufacturing,” International Journal of Industrial Organization, 23(5-6), 355-379.

Vonortas, N.S., 1994, “Inter-firm cooperation with imperfectly appropriable research,” International Journal of Industrial Organization, 12(3), 413-435.